Compare AbCellera Biologics Inc (ABCL) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Global X NASDAQ 100 Covered Call ETF trades at $18.04. Which is the better fit depends on your goals.
| ABCL | QYLD | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $18.52 |
52-Week Low | $2.78 | $16.46 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
QYLD trades at $18.34, up 1.38% with a bullish technical signal driven by moving averages, though oscillators remain neutral. The ETF's covered-call strategy generates high monthly dividends, with recent payouts of $0.19 and $0.18, but long-term performance has lagged the Nasdaq-100's growth. News highlights concerns over NAV erosion despite the 12% yield.
Outlook: High income appeals to retirees, but capital appreciation is limited by the covered-call structure. Risks include underperformance in bull markets and concentration in tech. Investors prioritize yield over growth, yet must monitor erosion risks highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
